Rubicon Research — 360° view

Rubicon Research, a company in the Pharmaceuticals industry, reported revenue of ₹576 crore and net profit of ₹90 crore for the September 2026 quarter.

Rubicon Research (NSE: RUBICON) closed at ₹1,718.70 on 20 Nov 2026, up 146.9% over the past year. Its market capitalisation is ₹28,451 crore and it trades at 87.6 times earnings.

Share price
₹1,718.70 (20 Nov 2026)
Market cap
₹28,451 Cr (20 Nov 2026)
P/E
87.58 (20 Nov 2026)
Revenue
₹576 Cr (September 2026 quarter)
Net profit
₹90 Cr (September 2026 quarter)
ROCE
28.4% (FY26)
ROE
27.0% (FY26)
Book value
₹85.6 (FY26)
Dividend yield
0.09% (last 12 months to 20 Nov 2026)
52-week high / low
₹1,899.00 / ₹609.25 (20 Nov 2026)
1-year return
146.9% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: RUBICON

Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, & commercialization of differentiated formulations.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.